This article has been updated with information about NGS cancer panels with FDA-approved companion diagnostic indications.
NEW YORK (GenomeWeb) – CMS on Friday finalized the draft national coverage determination it issued last year on next-generation sequencing cancer panels, altering the determination to no longer include coverage with evidence development (CED) for tests that haven't been approved by the US Food and Drug Administration.